Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Oncology

Topics

Biology

Biochemistry

Medicine

Epidemiology

Immunology

Show all topics

DOI

10.1016/s1470-2045(05)70101-7